21.Wang M, Fan Y, Sun M, et al. Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm,
[16].Kwon CS, Lin HM, Crossland V, et al. Non-small cell lung cancer with EGFR exon 20 insertion mutation: a systematic literature review and pooled analysis of patient outcomes [published online ahead of print, 2022 Ma...
3.MariaE.Arcila,KhedoudjaNafa,JamieE.Chaft,etal.EGFRExon20InsertionMutationsinLungAdenocarcinomas:Prevalence,MolecularHeterogeneity,andClinicopathologicCharacteristics.MolCancerTher.2012(2):220–229 责任编辑|青霉素 声明:本文观点仅代表作者本人,不代表药智头条立场,欢迎留言交流补充;如需转载,请务必注明文章作者和来源。
21.Wang M, Fan Y, Sun M, et al. Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial. Lancet Respir Med. 2024;12(3):2...
EGFR exon 20 insertion mutation in advanced thymic squamous cell carcinoma: Response to apatinib and clinical outcomesAdvanced thymic carcinoma (TC)anti゛ngiogenic therapyapatinibchemotherapyimmunotherapyThymic carcinoma (TC) is a rare malignant tumor of the mediastinum with occult onset, rapid development,...
EGFR exon 20 insertion mutation in Japanese lung cancer Lung Cancer, 58 (2007), pp. 324-328, 10.1016/j.lungcan.2007.06.024 View PDFView articleView in ScopusGoogle Scholar [17] Takeda’s EXKIVITYTM (mobocertinib) Approved by U.S. FDA as the First Oral Therapy Specifically Designed for...
Epidemiological and clinical burden of EGFR exon 20 insertion in advanced non-small cell lung cancer: a systematic literature review. Abstract presented at: World Conference on Lung Cancer Annual Meeting. January 29, 2021; Singapore. 27 Zhang YL, et al. The prevalence of EGFR mutation in ...
et al. Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: results from the expanded access program. Eur. J. Cancer https://doi.org/10.1016/j.ejca.2021.02.038 (2021). Le, X. et al. Poziotinib in non-small-cell lung cancer harboring HER2 exon 20 insertion ...
Epidermal growth factor receptor exon 20 insertion (EGFRex20ins) mutations represent approximately 4–12% of EGFR mutations and are generally refractory to the 1st and 2nd generation EGFR tyrosine kinase inhibitors (TKIs). Development of effective therap
EGFRmutations were confirmed to be truncal events (mutations present in all sectors of a tumor) in every case regardless of the mutation type (L858R, exon 19 deletion or exon 20 insertion), underscoring its role as an early tumor initiating driver event (Fig.1a, Supplementary Data2). Besides...